Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Plus Chemotherapy in SCLC Transformed From EGFR-mutated NSCLC
NCT05957510Phase 2Active, not recruiting
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Jul 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in small cell lung cancer (SCLC), sponsored by Guangdong Association of Clinical Trials. Started Jul 2023; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05957510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957510.